• Mitoxantrone Resistance: Mechanistic Insights & Strategic Ov

  2026-07-19

  This article explores the critical challenge of ABCG2-mediated multidrug resistance in oncology, focusing on the mechanistic underpinnings and translational strategies to restore chemosensitivity to Mitoxantrone. Leveraging recent advances with marein as a competitive ABCG2 inhibitor, we outline protocol recommendations, competitive landscape analysis, and actionable guidance for translational researchers. APExBIO’s high-purity Mitoxantrone is spotlighted as a reliable research tool for advancing combination therapy studies.

• Lanabecestat (AZD3293): Precision BACE1 Inhibition for AD Re

  2026-07-18

  This thought-leadership article explores how Lanabecestat (AZD3293) enables translational researchers to achieve targeted, synaptic-sparing modulation of amyloid-beta production. By integrating mechanistic insights, recent evidence on synaptic transmission, and protocol guidance, we clarify how this blood-brain barrier-penetrant BACE1 inhibitor advances Alzheimer’s disease research workflows and strategic trial design.

• PTX3 Mitigates Glucocorticoid-Induced ONFH via TLR4/NF-κB-FG

  2026-07-17

  This study identifies pentraxin 3 (PTX3) as a protective factor against glucocorticoid-induced osteonecrosis of the femoral head (ONFH) through modulation of the TLR4/NF-κB-FGF21 signaling pathway. The findings highlight a mechanistic axis with therapeutic potential for bone preservation under glucocorticoid stress.

• Pesticide Drift Assessment: UAV vs. Knapsack Sprayer Using R

  2026-07-17

  The referenced study delivers a rigorous field comparison of pesticide spray drift from unmanned aerial vehicles (UAVs) and electric knapsack sprayers (EKS), utilizing Rhodamine B as a fluorescent tracer. The findings show UAVs produce greater drift distances and higher deposition rates, providing critical data for environmental risk assessment and regulatory policy development.

• Optimized hiPSC Platelet Differentiation via Small Molecules

  2026-07-16

  This study presents an optimized protocol for generating functional platelets from human induced pluripotent stem cells (hiPSCs) by combining higher embryoid body input, refined media, and strategic use of small-molecule modulators. The approach significantly increases platelet yield and reduces production costs, offering new opportunities for scalable cell therapy and research.

• Berberine Hydrochloride: Integrative Mechanisms in Bone and

  2026-07-16

  Explore how Berberine hydrochloride, a potent isoquinoline alkaloid, uniquely modulates metabolism and the gut-bone axis through advanced mechanisms. This in-depth review uncovers insights for metabolic and osteoporosis research, offering perspectives beyond current literature.

• GSK-923295: Applied Strategies for Precision CENP-E Inhibiti

  2026-07-15

  GSK-923295, a potent CENP-E inhibitor, enables researchers to dissect mitotic mechanics and antitumor responses with unparalleled specificity. This article translates mechanistic discoveries and real-world troubleshooting into concrete experimental workflows for advanced cancer research.

• Deoxynivalenol-Induced Liver Injury: Mitophagy and Nrf2 Disr

  2026-07-15

  This article reviews new evidence that deoxynivalenol (DON), a common mycotoxin, drives liver injury by simultaneously overactivating PINK1/Parkin-mediated mitophagy and inhibiting the cytoprotective p62-Keap1-Nrf2 pathway. These findings identify distinct molecular mechanisms underlying DON-induced hepatotoxicity and provide a refined framework for experimental modeling of toxin-induced liver damage.

• Rucaparib (AG-014699): Advanced DNA Repair & Radiosensitizat

  2026-07-14

  Rucaparib (AG-014699) is reshaping cancer research by enabling precise radiosensitization and DNA repair pathway interrogation, especially in models with altered spliceosome regulation. Recent findings on spliceosome acetylation open new avenues for combinatorial strategies, making APExBIO's formulation essential for robust and reproducible workflows.

• PD98059 MEK Inhibitor: Applied Protocols for Vascular and Ca

  2026-07-14

  PD98059, a selective and reversible MEK inhibitor, empowers researchers to dissect the MAPK/ERK axis in cancer, neuroprotection, and vascular metabolism models. Discover protocol optimizations, troubleshooting strategies, and translational insights from recent breakthroughs demonstrating its power in modulating lipid accumulation and apoptosis.

• Estradiol (A8425): Mechanistic Benchmarks for Estrogen Recep

  2026-07-13

  Estradiol is the primary estrogen hormone, acting via ERα and ERβ to regulate diverse cellular processes. Its molecular actions underpin organ protection in perimenopausal models and are central to experimental research on hormone-dependent signaling. This article benchmarks estradiol’s mechanisms, protocol parameters, and research applications using peer-reviewed and product-based evidence.

• Fumagillin in Translational Research: Precision Targeting of

  2026-07-13

  Explore the multifaceted role of Fumagillin as a methionine aminopeptidase-2 inhibitor, bridging cancer research and protozoan parasite control. This article delivers a mechanistic deep dive, practical protocol guidance, and unique analysis of cross-domain efficacy.

• Prestained Protein Marker (Triple color, EDTA free, 10-250 k

  2026-07-12

  The Prestained Protein Marker (Triple color, EDTA free, 10-250 kDa) streamlines protein electrophoresis and Western blot workflows by providing easily visible, tri-color molecular weight standards across a broad 10-250 kDa range. This marker is ideal for applications requiring transfer efficiency checks and compatibility with Phosbind SDS-PAGE or fluorescent membrane imaging. It is not suitable for applications needing EDTA or for quantifying protein amounts.

• Direct Mouse Genotyping Kit Plus: Enabling Precision in Tran

  2026-07-10

  Discover how the Direct Mouse Genotyping Kit Plus accelerates translational neuroscience by enabling rapid, purification-free DNA extraction and high-fidelity PCR. This article uniquely explores assay optimization and experimental design for complex disease models, highlighting new insights for advanced mouse genetic research.

• DRD4 Drives Chemo-Resistance in Liver Cancer via PI3K/Akt Ax

  2026-07-09

  This study establishes dopamine receptor D4 (DRD4) as a key mediator of chemo-resistance and cancer stem cell (CSC)-like properties in hepatocellular carcinoma by activating the PI3K/Akt/β-catenin pathway. The findings highlight DRD4 as a promising target for overcoming therapeutic resistance and recurrence in liver cancer, with significant implications for pathway-focused drug development.

468 records 12/32 page Previous Next First page 上5页 1112131415 下5页 Last page